Catalyst Pharmaceuticals raises FY22 revenue view to $205M-$210M from $195-$205M

Consensus $205.03M. The company said, "The Company has increased its forecast for the full year 2022 total revenues to be in the range of between $205 million and $210 million, representing a 46% – 49% increase in total revenues compared to 2021, with cash operating expenses for the full year 2022 expected to be in the range of $65 million to $70 million and non-GAAP net income expected to be in the range of $100-105 million. Key guidance assumptions included in these forecasts reflect, among other risks, continued recovery in healthcare activity throughout 2022 as it relates to the current COVID-19 environment."